EUVIMEDEUVIMED entdecken
Fallbericht

From progression to complete remission – a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma

Bohuňovská Kateřina

Klinicka onkologie · 15.06.2026 · 39 (3) · 195-198

DOI: 10.48095/ccko2026195 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Klinicka onkologie, online erschienen am 15.06.2026. Verfasst von Bohuňovská Kateřina. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Pyrimidines, Receptor, Fibroblast Growth Factor, Type 2, Bile Duct Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaPyrimidinesReceptor, Fibroblast Growth Factor, Type 2Bile Duct NeoplasmsMorpholinesAntineoplastic AgentsHumansMiddle AgedMaleRemission InductionDisease ProgressionPyrroles

Stichwörter der Autor:innen

FGFR tyrosine kinase inhibitorcholangiocarcinomapemigatinibtargeted therapy

Substanzen

PyrimidinespemigatinibReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanMorpholinesAntineoplastic AgentsPyrroles

Zitieren

APA

Kateřina, B. (2026). From progression to complete remission – a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma. Klinicka onkologie, 39(3), 195-198. https://doi.org/10.48095/ccko2026195

Vancouver

Kateřina B. From progression to complete remission – a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma. Klinicka onkologie. 2026;39(3):195-198. doi:10.48095/ccko2026195

BibTeX
@article{Kateina2026,
  author = {Kateřina, Bohuňovská},
  title = {From progression to complete remission – a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma},
  journal = {Klinicka onkologie},
  year = {2026},
  volume = {39},
  number = {3},
  pages = {195--198},
  doi = {10.48095/ccko2026195}
}
Kostenlos starten →